| Quarterly Financials | Mar 2015 | Jun 2015 | Sept 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sept 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sept 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
Revenue  | 3,071 | 3,157 | 3,250 | 3,417 | 4,144 | 4,424 | 4,243 | 4,511 | 4,209 | 3,839 | 3,952 | 3,929 | 4,125 | 3,960 | 4,122 | 3,872 | 3,922 | 3,922 | 4,007 | 3,844 | 4,084 | 3,513 | 3,807 | 3,939 | 3,808 | 4,265 | 4,076 | 4,122 | 3,880 | 3,610 | 4,106 | 4,263 | 4,368 | 4,765 | 4,980 | 5,109 | 4,924 | 5,582 | 5,539 | 5,672 | 5,619 | 6,243 |
| Expenses | 2,289 | 2,331 | 2,667 | 2,702 | 2,883 | 3,157 | 3,260 | 3,264 | 3,472 | 3,104 | 3,099 | 3,287 | 4,789 | 3,329 | 3,401 | 3,608 | 3,107 | 3,131 | 3,788 | 3,629 | 3,320 | 3,040 | 3,254 | 3,239 | 3,066 | 3,306 | 5,415 | 3,791 | 3,615 | 3,512 | 3,693 | 3,790 | 3,852 | 3,958 | 4,121 | 4,160 | 3,964 | 4,359 | 4,332 | 4,412 | 4,346 | 4,541 |
| EBITDA | 783 | 825 | 583 | 715 | 1,261 | 1,268 | 983 | 1,246 | 737 | 735 | 853 | 642 | -665 | 631 | 721 | 264 | 814 | 791 | 219 | 215 | 763 | 473 | 553 | 700 | 742 | 960 | -1,339 | 331 | 265 | 98 | 414 | 473 | 515 | 807 | 859 | 950 | 960 | 1,223 | 1,207 | 1,261 | 1,273 | 1,702 |
| Operating Profit % | 25 % | 24 % | 16 % | 19 % | 30 % | 27 % | 23 % | 26 % | 17 % | 18 % | 20 % | 16 % | -20 % | 12 % | 13 % | 6 % | 18 % | 18 % | 1 % | 2 % | 12 % | 12 % | 14 % | 17 % | 18 % | 22 % | -35 % | 7 % | 6 % | 3 % | 10 % | 11 % | 11 % | 17 % | 17 % | 18 % | 19 % | 21 % | 21 % | 21 % | 22 % | 26 % |
| Depreciation | 107 | 101 | 116 | 122 | 149 | 203 | 211 | 231 | 267 | 261 | 272 | 280 | 273 | 259 | 266 | 219 | 219 | 250 | 253 | 253 | 214 | 215 | 213 | 244 | 216 | 209 | 919 | 203 | 327 | 193 | 204 | 220 | 264 | 235 | 248 | 257 | 457 | 248 | 257 | 272 | 393 | 299 |
| Interest | 3 | 7 | 24 | 10 | 31 | 35 | 29 | 48 | 41 | 44 | 48 | 54 | 59 | 69 | 74 | 79 | 84 | 84 | 83 | 89 | 107 | 44 | 34 | 31 | 32 | 34 | 34 | 33 | 42 | 43 | 55 | 84 | 93 | 86 | 81 | 74 | 71 | 68 | 71 | 67 | 89 | 92 |
| Profit Before Tax | 697 | 792 | 581 | 781 | 1,170 | 1,156 | 822 | 1,045 | 520 | 494 | 611 | 383 | -941 | 384 | 441 | 93 | 591 | 518 | -54 | -73 | 496 | 273 | 360 | 525 | 518 | 751 | -2,205 | 167 | -85 | 2 | 210 | 246 | 259 | 559 | 630 | 736 | 498 | 993 | 1,055 | 1,071 | 896 | 1,416 |
| Tax | 136 | 224 | 158 | 255 | 417 | 273 | 159 | 410 | 137 | 137 | 154 | 161 | -163 | 181 | 173 | 245 | 294 | 216 | 70 | 767 | 105 | 164 | 147 | 84 | 54 | 202 | -110 | -382 | 427 | 89 | 75 | 89 | 16 | 106 | 134 | 117 | 130 | 188 | 195 | 212 | 114 | 194 |
| Net Profit | 561 | 568 | 422 | 526 | 753 | 883 | 663 | 636 | 384 | 357 | 457 | 222 | -778 | 203 | 269 | -152 | 296 | 303 | -123 | -840 | 391 | 109 | 214 | 441 | 464 | 548 | -2,095 | 549 | -512 | -87 | 135 | 158 | 242 | 453 | 495 | 619 | 368 | 806 | 860 | 859 | 782 | 1,222 |
| EPS in ₹ | 12.17 | 12.65 | 9.34 | 11.67 | 16.63 | 19.57 | 14.69 | 14.04 | 8.42 | 7.93 | 10.07 | 4.91 | -17.33 | 6.40 | 5.88 | -3.37 | 6.55 | 6.69 | -2.72 | -18.56 | 8.64 | 2.36 | 4.66 | 9.67 | 10.15 | 11.96 | -46.22 | 12.01 | -11.40 | -1.96 | 2.85 | 3.38 | 5.19 | 9.94 | 10.76 | 13.47 | 7.89 | 17.58 | 18.70 | 18.75 | 16.93 | 26.70 |
Lupin
Lupin
1,905.60
-19.20
(-1.00%)
There are new updates from the company1 day ago
View
Key Fundamentals
Market Cap
87,916.10 Cr
EPS
71.95
PE Ratio
23.93
Dividend Yield
0.62 %
Industry
Healthcare 52 Week High
2,402.90
52 Week Low
1,795.20
PB Ratio
5.15
Debt to Equity
0.27
Sector
Pharmaceuticals Analyst Rating and Forecast
- By Refinitiv from35 analysts
Actual
Company News
View All News
Lupin announced plans to establish a $250 million pharmaceutical manufacturing plant in Coral Springs. The facility is expected to create 200 new jobs by 2030 and will focus on producing 25 respiratory medicines. This represents a significant investment in the company's manufacturing capabilities and expansion into respiratory drug production.
Lupin has launched Liraglutide injection in the United States. The product had an estimated annual sale of USD 350 million in the US market. Additionally, the US FDA has classified the inspection of Lupin's Pithampur Unit-2 as 'Official Action Indicated' and concluded the inspection with four observations.
Lupin received an 'official action indicated' (OAI) classification from the USFDA following inspections at its Pithampur Unit 2 manufacturing facility from July 8-17. The inspection concluded with Form 483 containing four observations. The company is working with regulators to resolve compliance issues and maintain good manufacturing practices standards. Separately, Lupin launched Liraglutide injection in the United States for blood sugar control in adults and children aged 10 years and above with type 2 diabetes. The injection is bioequivalent to Novo Nordisk's Victoza, which has annual US sales of around $350 million. Lupin shares closed 0.3% lower at ₹1,975 and have declined 16.5% year-to-date.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,631.60 | #1 3,96,634.10 | 34.59 | #1 54,729.00 | 9.71 | #1 10,980 | -19.84 | 52.19 | |
6,120.50 | 1,62,055.30 | 67.06 | 9,712.00 | 18.67 | 2,191 | 26.74 | 56.39 | |
1,494.60 | 1,22,237.40 | 22.67 | 28,409.50 | 7.12 | 5,291 | 9.88 | 38.43 | |
3,569.00 | 1,19,704.80 | 59.08 | 11,539.40 | 6.99 | 1,911 | 19.91 | 49.24 | |
1,234.50 | 1,04,201.50 | #1 18.34 | 33,741.20 | 16.73 | 5,725 | 1.26 | 39.35 | |
2,454.90 | 1,02,393.00 | 53.53 | 12,744.20 | #1 20.90 | 2,007 | -18.14 | 39.95 | |
985.95 | 99,405.90 | 21.46 | 23,511.00 | 18.55 | 4,615 | 2.60 | 42.63 | |
1,905.60 | #8 87,916.10 | #4 23.93 | #5 22,909.50 | #5 13.74 | #5 3,306 | #1 51.64 | 40.58 | |
5,493.50 | 65,665.10 | 28.86 | 13,458.30 | 3.70 | 2,216 | 21.39 | 58.27 | |
29,925.00 | 63,376.00 | 43.95 | 6,684.70 | 9.64 | 1,414 | 11.55 | 38.74 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
13.74 %
Net Income Growth
70.82 %
Cash Flow Change
-17.77 %
ROE
41.95 %
ROCE
20.69 %
EBITDA Margin (Avg.)
22.54 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 13,138 | 22,625 | 26,607 | 26,305 | 27,949 | 24,984 | 23,610 | 21,821 | 22,956 | 23,997 | 29,205 |
| Fixed Assets | 4,368 | 8,717 | 11,033 | 10,362 | 11,087 | 7,938 | 7,881 | 7,382 | 8,355 | 8,878 | 9,719 |
| Current Assets | 7,832 | 9,887 | 11,953 | 12,210 | 13,854 | 15,413 | 13,986 | 12,458 | 12,451 | 13,448 | 16,799 |
| Capital Work in Progress | 576 | 2,702 | 2,133 | 2,598 | 1,640 | 940 | 1,066 | 1,146 | 1,238 | 773 | 517 |
| Investments | 1,656 | 16 | 2,136 | 262 | 2,296 | 2,374 | 2,455 | 900 | 517 | 1,075 | 1,146 |
| Other Assets | 6,538 | 11,189 | 11,305 | 13,084 | 12,928 | 13,732 | 12,209 | 12,393 | 12,846 | 13,272 | 17,823 |
| Total Liabilities | 13,138 | 22,625 | 26,607 | 26,305 | 27,949 | 24,984 | 23,610 | 21,821 | 22,956 | 23,997 | 29,205 |
| Current Liabilities | 3,729 | 5,061 | 6,121 | 5,096 | 6,130 | 9,225 | 8,436 | 8,498 | 9,265 | 8,502 | 8,961 |
| Non Current Liabilities | 510 | 6,368 | 6,955 | 7,593 | 8,030 | 3,178 | 1,316 | 1,101 | 1,148 | 1,122 | 2,949 |
| Total Equity | 8,898 | 11,196 | 13,532 | 13,617 | 13,789 | 12,581 | 13,858 | 12,222 | 12,543 | 14,374 | 17,294 |
| Reserve & Surplus | 8,784 | 11,073 | 13,407 | 13,487 | 13,652 | 12,446 | 13,712 | 12,062 | 12,374 | 14,199 | 17,112 |
| Share Capital | 90 | 90 | 90 | 90 | 91 | 91 | 91 | 91 | 91 | 91 | 91 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 1,502 | -1,315 | 2,019 | 729 | -872 | 1,685 | -1,303 | 87 | 273 | -248 | 560 |
| Investing Activities | -1,034 | -6,769 | -2,527 | 470 | -3,283 | 1,107 | -1,240 | 1,292 | -1,287 | -1,712 | -4,172 |
| Operating Activities | 2,733 | -382 | 4,114 | 1,751 | 1,666 | 1,469 | 1,822 | 367 | 1,897 | 3,648 | 3,000 |
| Financing Activities | -197 | 5,836 | 433 | -1,492 | 744 | -891 | -1,885 | -1,572 | -337 | -2,184 | 1,732 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
| Promoter | 46.86 % | 46.84 % | 46.83 % | 46.81 % | 46.78 % | 47.10 % | 47.11 % | 47.10 % | 47.08 % | 47.07 % | 47.05 % | 47.04 % | 47.01 % | 46.98 % | 46.96 % | 46.95 % | 46.92 % | 46.90 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 16.11 % | 18.28 % | 19.32 % | 21.50 % | 22.04 % | 21.46 % | 21.25 % |
| DIIs | 22.08 % | 21.68 % | 24.38 % | 24.76 % | 26.84 % | 26.82 % | 27.54 % | 29.38 % | 29.21 % | 28.98 % | 29.42 % | 29.73 % | 27.76 % | 26.78 % | 25.09 % | 24.74 % | 25.41 % | 25.56 % |
| Government | 0.29 % | 0.28 % | 0.28 % | 0.28 % | 0.29 % | 0.29 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % | 0.01 % |
| Public / Retail | 10.02 % | 9.91 % | 10.18 % | 9.99 % | 8.53 % | 8.59 % | 8.41 % | 8.06 % | 7.86 % | 7.06 % | 6.24 % | 5.87 % | 5.70 % | 5.65 % | 5.29 % | 5.17 % | 5.10 % | 5.23 % |
| Others | 20.75 % | 21.29 % | 18.34 % | 18.16 % | 17.57 % | 17.19 % | 16.94 % | 15.45 % | 15.85 % | 16.89 % | 17.27 % | 1.23 % | 1.23 % | 1.26 % | 1.15 % | 1.10 % | 1.10 % | 1.05 % |
| No of Share Holders | 0 | 2,93,782 | 3,02,292 | 3,61,288 | 3,61,862 | 3,78,547 | 3,82,828 | 3,78,011 | 3,60,677 | 3,22,678 | 2,89,074 | 2,81,542 | 2,80,248 | 2,88,537 | 2,79,280 | 2,81,988 | 2,83,210 | 2,86,604 |
Dividend History
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 7.5 | 5 | 5 | 6 | 6.5 | 4 | 4 | 8 | 12 |
| Dividend Yield (%) | 0.00 | 1.02 | 0.68 | 0.85 | 0.59 | 0.87 | 0.61 | 0.25 | 0.39 | 0.62 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 28 Jul 2021 |  Dividend | ₹ 6.50 /share | 27 Jul 2021 | 1,212.25 | 1,111.60 |
| 15 Jul 2022 | Dividend | ₹ 4.00 /share | 14 Jul 2022 | 683.30 | 643.20 |
| 14 Jul 2023 | Dividend | ₹ 4.00 /share | 14 Jul 2023 | 732.25 | 930.75 |
| 16 Jul 2024 | Dividend | ₹ 8.00 /share | 16 Jul 2024 | 1,655.25 | 1,832.10 |
| 02 Aug 2024 |  Annual General Meeting | NA | 02 Aug 2024 | 1,778.90 | 1,953.55 |
| 07 Nov 2024 |  Quarterly Result Announcement | NA | 07 Nov 2024 | 2,151.95 | 2,166.05 |
| 11 Feb 2025 | Quarterly Result Announcement | NA | 11 Feb 2025 | 2,134.25 | 2,169.40 |
| 14 May 2025 | Quarterly Result Announcement | NA | 14 May 2025 | 2,107.70 | 2,063.00 |
| 25 Jul 2025 | Dividend | ₹ 12.00 /share | 25 Jul 2025 | 2,063.00 | 1,943.40 |
| 05 Aug 2025 | Quarterly Result Announcement | NA | 05 Aug 2025 | 1,930.85 | 1,882.20 |
| 11 Aug 2025 | Annual General Meeting | NA | 11 Aug 2025 | 1,894.70 | 1,918.00 |
Announcements
Announcement under Regulation 30 (LODR)-Press Release / Media Release
2 hours ago
2 hours agoCompliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 20181 day ago
1 day agoU.S. FDA Has Determined The Inspection Of Companys Pithampur Unit-2 Manufacturing Facility As Official Action Indicated.4 days ago
4 days agoAnnouncement under Regulation 30 (LODR)-Press Release / Media Release5 days ago
5 days agoAnnouncement under Regulation 30 (LODR)-Press Release / Media Release7 days ago
7 days agoAnnouncement under Regulation 30 (LODR)-Press Release / Media Release8 days ago
8 days agoAnnouncement under Regulation 30 (LODR)-Change in Management8 days ago
8 days agoAnnouncement under Regulation 30 (LODR)-Acquisition9 days ago
9 days agoClosure of Trading WindowSep 26, 2025
Sep 26, 2025 Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportSep 25, 2025
Sep 25, 2025Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotSep 25, 2025
Sep 25, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseSep 24, 2025
Sep 24, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSSep 23, 2025
Sep 23, 2025U.S. FDA Has Conducted A Product-Specific Pre-Approval Inspection At The CompanyS Pune Biotech Facility.Sep 20, 2025
Sep 20, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseSep 17, 2025
Sep 17, 2025U.S. FDA Has Conducted An Inspection Of CompanyS Injectable Facility At Nagpur.Sep 16, 2025
Sep 16, 2025ESG Rating By ESG Risk Assessments And Insights Limited.Sep 13, 2025
Sep 13, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 11, 2025
Sep 11, 2025U.S. FDA Has Conducted A Product-Specific Pre-Approval Inspection At The CompanyS Chhatrapati Sambhajinagar (Aurangabad) Manufacturing FacilitySep 06, 2025
Sep 06, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 03, 2025
Sep 03, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseSep 03, 2025
Sep 03, 2025ESG Rating By Crisil ESG Ratings & Analytics Ltd.Aug 29, 2025
Aug 29, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 27, 2025
Aug 27, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 27, 2025
Aug 27, 2025Shareholder Meeting / Postal Ballot-Notice of Postal BallotAug 26, 2025
Aug 26, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSAug 21, 2025
Aug 21, 2025Announcement under Regulation 30 (LODR)-Change in DirectorateAug 20, 2025
Aug 20, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 20, 2025
Aug 20, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 12, 2025
Aug 12, 2025Announcement under Regulation 30 (LODR)-Change in DirectorateAug 11, 2025
Aug 11, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportAug 11, 2025
Aug 11, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMAug 11, 2025
Aug 11, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 11, 2025
Aug 11, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 11, 2025
Aug 11, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 08, 2025
Aug 08, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 07, 2025
Aug 07, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 06, 2025
Aug 06, 2025Announcement under Regulation 30 (LODR)-Investor PresentationAug 06, 2025
Aug 06, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 05, 2025
Aug 05, 2025Board Meeting Outcome for Approval Of The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended June 30 2025.Aug 05, 2025
Aug 05, 2025Approval Of The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended June 30 2025.Aug 05, 2025
Aug 05, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSAug 05, 2025
Aug 05, 2025Rumour verification - Regulation 30(11)Aug 01, 2025
Aug 01, 2025Clarification sought from Lupin LtdAug 01, 2025
Aug 01, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 25, 2025
Jul 25, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 24, 2025
Jul 24, 2025Reg. 34 (1) Annual Report.Jul 23, 2025
Jul 23, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 22, 2025
Jul 22, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 21, 2025
Jul 21, 2025Board Meeting Intimation for Considering And Taking On Record Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended June 30 2025.Jul 21, 2025
Jul 21, 2025Mutual Fund Holdings
HDFC Balanced Advantage Fund Direct-Growth 
Mirae Asset Large & Midcap Fund Direct-Growth 
ICICI Prudential Value Direct-Growth 
SBI ELSS Tax Saver Fund Direct-Growth 
Nippon India Pharma Fund Direct-Growth 
Axis Midcap Direct Plan-Growth 
Sundaram Mid Cap Fund Direct-Growth 
Kotak Arbitrage Fund Direct-Growth 
Invesco India Arbitrage Fund Direct-Growth 
Franklin India Flexi Cap Fund Direct-Growth 
Edelweiss Mid Cap Direct Plan-Growth Technical Indicators
RSI(14)
Neutral 43.17
ATR(14)
Less Volatile 42.87
STOCH(9,6)
Neutral 26.54
STOCH RSI(14)
Neutral 24.92
MACD(12,26)
Bearish -9.18
ADX(14)
Weak Trend 18.05
UO(9)
Bearish 35.75
ROC(12)
Downtrend And Accelerating -5.95
WillR(14)
Oversold -85.55
About Lupin
Lupin is a global pharmaceutical company producing branded and generic formulations, biotechnology products, and active pharmaceutical ingredients. Founded in 1983, it operates in over 100 markets, specializing in cardiovascular, diabetology, asthma, pediatric, central nervous system, gastrointestinal, anti-infective, and NSAID therapies. Lupin is a leader in anti-TB and cephalosporins segments. The company has expanded through acquisitions and partnerships, entering markets in Japan, Germany, Australia, South Africa, and the Philippines. Lupin has manufacturing facilities in various locations and has received FDA approvals for multiple generic drugs. The company has also launched innovative products and entered strategic alliances with other pharmaceutical companies for drug development and marketing.
Website
Chairperson NameM D Gupta
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
